PCSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PCSA is not a good buy right now. The chart structure is still bearish (short/medium/long MAs stacked bearishly), there are no Intellectia buy signals today, and the latest quarter shows continued losses with sharply weaker EPS YoY. For an impatient buyer who wants immediate traction, the setup does not justify entry at the current pre-market price (~3.14).
Price/levels: Pre-market ~3.14 is below the pivot (3.355) and sitting just above S1 (3.049). That puts the stock in a weak zone where a break below ~3.05 increases downside risk toward S2 (2.861). Trend: Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), signaling a prevailing downtrend. Momentum: MACD histogram is positive (0.0986) but contracting, suggesting bullish momentum is fading rather than strengthening. RSI(6) ~40.8 is neutral-to-weak, not showing a strong oversold bounce signal.
Intellectia Proprietary Trading Signals
Near-term bias: Mixed-to-bearish. While pattern-based stats suggest a better 1-month drift (+5.63%), the next day/week expectations are slightly negative (-0.35% / -0.1%), which is not ideal for an impatient entry.
No news in the last week (no immediate negative headline overhang). Pattern-based projection indicates a potential positive 1-month move (~+5.63%), suggesting rebound potential if support holds near ~3.05.
indicates persistent downward pressure. MACD momentum is positive but weakening (contracting), implying rallies may fade. If ~3.05 (S
breaks, next support is meaningfully lower (~2.86).
Latest quarter: 2025/Q3. Revenue reported as 0 (0.00% YoY). Net income improved slightly to -3,436,573 (+1.53% YoY) but remains deeply negative. EPS fell to -1.81 (-92.99% YoY), indicating materially worse per-share performance YoY. Overall: still a loss-making profile with no revenue reported in the snapshot, which weakens the fundamental case for a near-term buy.
No analyst rating or price target change data was provided, so a Wall Street consensus trend cannot be confirmed. Pros typically argued by bulls (not evidenced here): any pipeline/clinical upside could re-rate the stock. Cons (supported by provided data): lack of revenue in the snapshot, ongoing losses, and a bearish technical trend. Trading sentiment signals: hedge funds neutral (no significant last-quarter trend), insiders neutral (no significant last-month trend). Politician/congress activity: no recent congress trading data available.
